These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
The FDA aims to make a decision by April 8, 2026
The new centre brings advanced corneal procedures pioneered in India
The companies aim to expand treatment options for millions living with metabolic disorders
Roche says its new assay “resolves this challenge by delivering accurate and specific results
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
Subscribe To Our Newsletter & Stay Updated
